|
A Novel Therapeutic Strategy for Parkinson's Disease based on the Gut Microbiota: A Rreview Article
|
Romina Kardan1    , Mohsen Nazari2 , Jaber Hemmati3 , Amjad Ahmadi4 , Mahtab Ashab5 |
1- Ph.D. Student of Neuroscience, Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran & Ph.D. Student of Neuroscience, Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
2- Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran & Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
3- Ph.D. Student of Bacteriology, Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran & Ph.D. Student of Bacteriology, Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
4- Ph.D. Student of Bacteriology, Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran & Ph.D. Student of Bacteriology, Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran , microbiology90@gmail.com
5- Bachelor of Biology, Department of Biology, Faculty of Basic Sciences, Payame Noor University of Pardis Branch, Tehran, Iran & Bachelor of Biology, Department of Biology, Faculty of Basic Sciences, Payame Noor University of Pardis Branch, Tehran, Iran |
|
|
Abstract: (1470 Views) |
Background and Aim: The gut microbiota, which is now recognized as an important organ of the human body, can have an impact on various neurological outcomes such as cogBackground and Aim: The gut microbiota, which is now recognized as an important organ of the human body, can have an impact on various neurological outcomes such as cognition, learning, and memory. The aim of this study was to investigate the relationship between gut microbiota and Parkinson's disease and also to highlight appropriate microbiota-based therapeutic approaches for Parkinson's disease
Materials and Methods: In this study, we searched and extracted the articles based on the keywords of "Parkinson's", "gut microbiota", "gut microbiome", "fecal microbiota", "fecal microbiome", "probiotic", and "gut-brain axis" from all data bases. Our inclusion criteria included English and Persian language articles, original articles and articles with open access, and the exclusion criteria of the study included articles other than English and Persian articles, articles without open access, meta-analysis and review articles. Finally, 38 articles were reviewed
and analyzed.
Results: Fecal microbiota transplant and probiotics laid the groundwork for identifying the mechanisms underlying the ability of the gut microbiota to influence a host's brain and behavior. It could help in prevention or early diagnosis of Parkinson's disease possibly through some peripheral biomarkers.
Conclusion: Recent studies have also shown that patients with Parkinson's disease have a disruption in gut microbiota balance (dysbiosis), but its exact role in causing the neurological disorder is still unknown. However, new approaches based on gut microbiota can be developed to prevent and treat neurological disorders such as Parkinson's disease. |
|
| Keywords: Microbiome, Gut-brain axis, Parkinson's disease, Probiotics |
|
|
Full-Text [PDF 518 kb]
(410 Downloads)
|
Type of Study: Review |
Subject:
Microbiology
Received: 2023/06/30 | Accepted: 2023/11/7 | Published: 2024/09/18
|
|
|
|
|
|
|
| References |
|
1. 1.Hosseinzadeh A, Baneshi MR, Sedighi B, Kermanchi J, Haghdoost AA. Estimation of Parkinson's Disease Prevalence and Its Geographical Variation in Iran. J Mazandaran Univ Med Sci. 2021;31(200):113-124. 2. Del Tredici K, Rüb U, De Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002;61(5):413-426. [ DOI:10.1093/jnen/61.5.413] [ PMID] 3. Castelli V, d'Angelo M, Lombardi F, Alfonsetti M, Antonosante A, Catanesi M, et al. Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson's disease models. Aging. 2020;12(5):4641-4659. [ DOI:10.18632/aging.102927] [ PMID] [ ] 4. Ueki A, Otsuka M. Life style risks of Parkinson's disease: association between decreased water intake and constipation. J Neurol. 2004;251:vii18-vii23. [ DOI:10.1007/s00415-004-1706-3] [ PMID] 5. Khosravi F, Hojati V, Entezari M, Hashemi M. Evaluation of neuroprotective effects of cobalamin (vitamin B12) in Parkinson's disease-Investigation of molecular mechanisms. Med Sci J of Islamic Azad Uni-Tehran 2021;33(4):381-392. 6. Surwase SN, Jadhav JP. Bioconversion of L-tyrosine to L-DOPA by a novel bacterium Bacillus sp. JPJ. J Amino Acids. 2011;41(2):495-506. [ DOI:10.1007/s00726-010-0768-z] [ PMID] 7. Browne HP, Forster SC, Anonye BO, Kumar N, Neville BA, Stares MD, et al. Culturing of 'unculturable'human microbiota reveals novel taxa and extensive sporulation. Nature. 2016;533(7604):543-546. [ DOI:10.1038/nature17645] [ PMID] [ ] 8. Çamcı G, Oğuz S. Association between Parkinson's disease and Helicobacter pylori. J Clin Neurol. 2016;12(2):147-150. [ DOI:10.3988/jcn.2016.12.2.147] [ PMID] [ ] 9. Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. J Mov Disord. 2015;30(3):350-358. [ DOI:10.1002/mds.26069] [ PMID] 10. Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PloS one. 2011;6(12):e28032. [ DOI:10.1371/journal.pone.0028032] [ PMID] [ ] 11. Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, et al. Colonic bacterial composition in Parkinson's disease. Mov Disord. 2015;30(10):1351-1360. [ DOI:10.1002/mds.26307] [ PMID] 12. Derkinderen P, Shannon KM, Brundin P. Gut feelings about smoking and coffee in Parkinson's disease. Mov Disord. 2014;29(8):976-979. [ DOI:10.1002/mds.25882] [ PMID] [ ] 13. Khandestan K, Pakpour B, Tajabadi Ebrahimi M. Effect of Lactobacillus paracasei probiotic in Parkinson's male rats. J Gorgan Univ Med Sci. 2020;22(3):65-72. 14. Kosiewicz MM, Zirnheld AL, Alard P. Gut microbiota, immunity, and disease: a complex relationship. Front microbiol. 2011;2:180. [ DOI:10.3389/fmicb.2011.00180] [ PMID] [ ] 15. Lotan D, Cunningham M, Joel D. Antibiotic treatment attenuates behavioral and neurochemical changes induced by exposure of rats to group a streptococcal antigen. PLoS One. 2014;9(6):e101257. [ DOI:10.1371/journal.pone.0101257] [ PMID] [ ] 16. Investigators NN-P. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. J Neurol. 2006;66(5):664-671. [ DOI:10.1212/01.wnl.0000201252.57661.e1] [ PMID] 17. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut dysbiosis is linked to hypertension. J Hypertens. 2015;65(6):1331-1340. [ DOI:10.1161/HYPERTENSIONAHA.115.05315] [ PMID] [ ] 18. Tallarida CS, Corley G, Kovalevich J, Yen W, Langford D, Rawls SM. Ceftriaxone attenuates locomotor activity induced by acute and repeated cocaine exposure in mice. Neurosci Lett. 2013;556:155-159. [ DOI:10.1016/j.neulet.2013.09.072] [ PMID] [ ] 19. Davey K, Cotter P, O'sullivan O, Crispie F, Dinan T, Cryan J, et al. Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat. Transl Psychiatry. 2013;3(10):e309-e309. [ DOI:10.1038/tp.2013.83] [ PMID] [ ] 20. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. PNAS. 2011;108(38):16050-16055. [ DOI:10.1073/pnas.1102999108] [ PMID] [ ] 21. Marselle MR, Hartig T, Cox DT, De Bell S, Knapp S, Lindley S, et al. Pathways linking biodiversity to human health: A conceptual framework. Environ Int. 2021;150:106420. [ DOI:10.1016/j.envint.2021.106420] [ PMID] 22. Gazerani P. Probiotics for Parkinson's disease. Int J Mol Sci. 2019;20(17):4121. [ DOI:10.3390/ijms20174121] [ PMID] [ ] 23. Hwang O. Role of oxidative stress in Parkinson's disease. Exp Neurobiol. 2013;22(1):11. [ DOI:10.5607/en.2013.22.1.11] [ PMID] [ ] 24. Miyake Y, Fukushima W, Tanaka K, Sasaki S, Kiyohara C, Tsuboi Y, et al. Dietary intake of antioxidant vitamins and risk of Parkinson's disease: a case-control study in Japan. Eur J Neurol. 2011;18(1):106-113. [ DOI:10.1111/j.1468-1331.2010.03088.x] [ PMID] 25. Smith MP, Fletcher-Turner A, Yurek DM, Cass WA. Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem Res. 2006;31:533-539. [ DOI:10.1007/s11064-006-9048-4] [ PMID] 26. Murakami K, Miyake Y, Sasaki S, Tanaka K, Fukushima W, Kiyohara C, et al. Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson's disease: a case-control study in Japan. Br J Nutr. 2010;104(5):757-764. [ DOI:10.1017/S0007114510001005] [ PMID] 27. Yoshii K, Hosomi K, Sawane K, Kunisawa J. Metabolism of dietary and microbial vitamin B family in the regulation of host immunity. Front nutr. 2019;6:48. [ DOI:10.3389/fnut.2019.00048] [ PMID] [ ] 28. Pompei A, Cordisco L, Amaretti A, Zanoni S, Matteuzzi D, Rossi M. Folate production by bifidobacteria as a potential probiotic property. Appl Environ Microbiol. 2007;73(1):179-185. [ DOI:10.1128/AEM.01763-06] [ PMID] [ ] 29. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. J Infect Dis. 2003;36(5):580-585. [ DOI:10.1086/367657] [ PMID] 30. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2012;9(2):88-96. [ DOI:10.1038/nrgastro.2011.244] [ PMID] 31. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012;10(11):735-742. [ DOI:10.1038/nrmicro2876] [ PMID] 32. Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. J Neurol. 2006;66(10 suppl 4):S24-S36. [ DOI:10.1212/WNL.66.10_suppl_4.S24] [ PMID] 33. Arai H, Furuya T, Mizuno Y, Mochizuki H. Inflammation and infection in Parkinsons disease. Histol Histopathol. 2006. 34. Beaman BL, Canfield D, Anderson J, Pate B, Calne D. Site-specific invasion of the basal ganglia by Nocardia asteroides GUH-2. Med Microbiol Immunol. 2000;188:161-168. [ DOI:10.1007/s004309900030] [ PMID] 35. Bu X-L, Wang X, Xiang Y, Shen L-L, Wang Q-H, Liu Y-H, et al. The association between infectious burden and Parkinson's disease: a case-control study. Park Relat Disord. 2015;21(8):877-881. [ DOI:10.1016/j.parkreldis.2015.05.015] [ PMID] 36. Matsui H, Ito H, Taniguchi Y, Inoue H, Takeda S, Takahashi R. Proteasome inhibition in medaka brain induces the features of Parkinson's disease. J Neurochem. 2010;115(1):178-187. [ DOI:10.1111/j.1471-4159.2010.06918.x] [ PMID] 37. Pablo J, Banack S, Cox P, Johnson T, Papapetropoulos S, Bradley W, et al. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol Scand. 2009;120(4):216-225. [ DOI:10.1111/j.1600-0404.2008.01150.x] [ PMID] 38. Scheperjans F, Pekkonen E, Kaakkola S, Auvinen P. Linking smoking, coffee, urate, and Parkinson's disease-a role for gut microbiota? J Parkinsons Dis. 2015;5(2):255-262. [ DOI:10.3233/JPD-150557] [ PMID] 39. Xu X, Fu Z, Le W. Exercise and Parkinson's disease. Int Rev Neurobiol. 2019;147:45-74. [ DOI:10.1016/bs.irn.2019.06.003] [ PMID] 40. Wall R, Cryan JF, Ross RP, Fitzgerald GF, Dinan TG, Stanton C. Bacterial neuroactive compounds produced by psychobiotics. J Endocrinol. 2014:221-239. [ DOI:10.1007/978-1-4939-0897-4_10] [ PMID] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Kardan R, Nazari M, Hemmati J, Ahmadi A, Ashab M. A Novel Therapeutic Strategy for Parkinson's Disease based on the Gut Microbiota: A Rreview Article. SJKU 2024; 29 (3) :127-138 URL: http://sjku.muk.ac.ir/article-1-7974-en.html
|
